- Series: Cancer Drug Discovery and Development
- Hardcover: 284 pages
- Publisher: Humana Press; 2005 edition (December 3, 2004)
- Language: English
- ISBN-10: 1588292002
- ISBN-13: 978-1588292001
- Product Dimensions: 6.1 x 0.7 x 9.2 inches
- Shipping Weight: 1.4 pounds (View shipping rates and policies)
- Average Customer Review: Be the first to review this item
- Amazon Best Sellers Rank: #6,521,237 in Books (See Top 100 in Books)
Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
To get the free app, enter your mobile phone number.
Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development) 2005th Edition
Use the Amazon App to scan ISBNs and compare prices.
The Amazon Book Review
Author interviews, book reviews, editors picks, and more. Read it now
"It offers everyone in the field of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects of cancer patients." - Neoplasma
From the Back Cover
Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics.
Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today.